EL7.AI
StocksMedium•19 November 2026•
4 min read

Celldex Has Not Confirmed Barzolvolimab Results in Atopic Dermatitis Trial

Key Facts

1The Phase 2 trial included 131 patients, assigned in a 1:1:1 ratio to 150 and 300 mg doses or placebo.
2The placebo-controlled comparison phase lasted 16 weeks, followed by a 16-week active-treatment phase.
3The company said about two-thirds of patients, estimated at about 1.7 million in the United States, do not achieve full control after first-line systemic treatment.
4Celldex expects to submit a biologics license application for barzolvolimab to treat chronic spontaneous urticaria in 2027.

The results of the Phase 2 trial of barzolvolimab for atopic dermatitis, and Celldex’s decision on whether to continue its development, could not be verified in the release published on November 19. The open official filing does not establish the result for the primary endpoint measuring itch, so it cannot be concluded that the trial failed or that the company discontinued the program for this indication. The company’s filing with the Securities and Exchange Commission provides the latest previously identified guidance, forecasting top-line results in late 2026. The company had said the trial began in December 2024 and completed enrollment in January 2026. Results therefore remained expected late in the year, with no confirmation of the study outcome in the open filing as of the date of the news report.

According to Celldex’s filing, the Phase 2 trial included 131 patients, randomly assigned in a 1:1:1 ratio to 150 or 300 mg doses of barzolvolimab or placebo. Treatment was administered by subcutaneous injection every 4 weeks after an initial 450 mg loading dose, with the corresponding group receiving placebo. The placebo-controlled comparison phase lasted 16 weeks, allowing the two doses to be compared with placebo. The study design did not end there: at week 16, participants in the placebo group were randomly reassigned to one of the active-treatment groups. Patients then entered another 16-week active-treatment phase, during which they received barzolvolimab every 4 weeks.

The primary objective was to assess the clinical efficacy of the two doses versus placebo using the Peak Pruritus Numerical Rating Scale at week 16, according to the company’s filing. The scale measures the severity of the worst itch in adults with moderate-to-severe atopic dermatitis. Secondary outcomes included patient-reported measures, among them assessments of disease change and severity and improvements in quality of life. The study was conducted at about 40 clinical sites in the United States. However, the available open filing does not confirm the scale’s change or the results for either dose, and does not allow an assessment of either dose against placebo.

The treatment need cited by the company in describing the study remains, in its assessment: about two-thirds of patients receiving first-line systemic treatment do not achieve full control of atopic dermatitis. The company estimated that this represents about 1.7 million patients in the United States. That figure provides context for developing additional treatments for the disease, but does not establish the outcome for barzolvolimab in the current trial. The company’s disclosure of this need also does not compare the drug with other treatments or estimate its chances of approval.

In barzolvolimab’s programs for other indications, Celldex has disclosed mixed results involving different diseases, which should not be treated as results from the atopic dermatitis trial. In the Phase 2 trial for prurigo nodularis, the study did not meet its primary or key secondary endpoints at week 12 for either dose. By contrast, the company said top-line results from its two Phase 3 trials for chronic spontaneous urticaria met the primary endpoint and all key secondary endpoints. It said efficacy continued or deepened between weeks 12 and 24 for that indication. These results relate to urticaria and prurigo nodularis and do not resolve the drug’s efficacy in atopic dermatitis.

For the chronic spontaneous urticaria program, the company said treatment in the two Phase 3 trials would continue through 52 weeks and that it expects to submit a biologics license application to the U.S. Food and Drug Administration in 2027. It also described safety and tolerability data through 24 weeks as favorable in those trials, and said efficacy continued or deepened from week 12 to week 24. This timeline concerns the urticaria program, not the atopic dermatitis trial. The atopic dermatitis study result and the decision on whether to continue developing the drug for that disease could not be verified in an open official source linked to the November 19 release.